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Abstract
Background Non-high-density lipoprotein cholesterol
(non-HDL-C) has been proposed as a predictor of cardio-
vascular disease (CVD) in the general population. The aim
of this study was to evaluate the utility of non-HDL-C in
predicting CV mortality in chronic hemodialysis (HD)
patients.
Methods We calculated the serum non-HDL-C level of
259 HD patients by subtracting their HDL-C levels from
their total cholesterol. Cox proportional hazards models
were used to estimate the hazards ratio (HR) for CV
mortality and the 95% confidence interval (CI). A receiver-
operating characteristic (ROC) analysis was performed to
estimate the relationship between sensitivity and specificity
of a diagnostic parameter.
Results There were 44 deaths (17.0%) during the follow-
up period, 33 (12.7%) of which were due to CVD. A
multivariate Cox analysis with adjustments for age, dia-
betes, dialysis vintage, systolic blood pressure, serum
albumin, and lipid levels showed that non-HDL-C was an
independent predictor of CV mortality (HR 1.015, 95% CI
1.004–1.025, p = 0.0083). An ROC analysis showed that
the plots of the non-HDL-C levels yielded significant
specificity and sensitivity for predicting the risk of CVD
mortality in HD patients [area under the curve (AUC)
0.62416; p = 0.0366; cutoff value 111.0 mg/dl]. The
Kaplan–Meier survival curves of HD patients showed
significant differences in CV mortality according to their
tertiles with respect to serum non-HDL-C levels
(p = 0.0165).
Conclusion The results of this study suggest that serum
non-HDL-C level is a significant CV mortality predictor of
chronic HD patients.
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Introduction
Cardiovascular disease (CVD) is the primary cause of
death of end-stage renal disease (ESRD) patients in Japan
[1], and intensive management of CV risk factors, includ-
ing dyslipidemia, has been proposed in order to reduce the
burden of CVD in hemodialysis (HD) patients. Most HD
patients have normal total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C) levels, but HD patients
tend to have low high-density lipoprotein cholesterol
(HDL-C) and high triglyceride (TG) levels [2]. Guidelines
for the management of patients with dyslipidemia and
chronic kidney disease have recently been published [3],
and the algorithms in the guidelines are based on fasting
lipid profile data, which can be difficult to obtain in
patients with diabetes mellitis (DM) and patients on an
afternoon or nighttime dialysis schedule.
The serum non-HDL-C level is the sum of the LDL-C,
intermediate-density lipoprotein-C, and very-LDL-C lev-
els, and as the non-HDL-C levels are strongly correlated
Y. Echida  K. Nitta (&)
Department of Medicine, Kidney Center,
Tokyo Women’s Medical University, 8-1 Kawada-cho,
Shinjuku-ku, Tokyo 162-8666, Japan
e-mail: knitta@kc.twmu.ac.jp
T. Ogawa  K. Otsuka
Department of Medicine, Medical Center East,
Tokyo Women’s Medical University, Tokyo, Japan
Y. Ando
Hidaka Hospital, Takasaki, Gunma, Japan
123
Clin Exp Nephrol (2012) 16:767–772
DOI 10.1007/s10157-012-0615-5
with apolipoprotein B (ApoB) levels, it has been suggested
that non-HDL-C levels may be a better marker of athero-
genic cholesterol than LDL-C levels [4]. The non-HDL-C
level can be easily calculated by subtracting the HDL-C
level from the TC level. Non-HDL-C levels have been
found to be a predictor of CVD in the general population
[5], and as TC and HDL-C data are similar, whether
measured in the fasting or nonfasting state, non-HDL-C is a
reliable marker for use in the general population. However,
the role of non-HDL-C in the mortality of HD patients has
not been extensively investigated [6]. The aim of this study
was to evaluate the utility of serum non-HDL-C level in
predicting CV mortality in chronic HD patients.
Materials and methods
This was a prospective cohort study conducted at the
Kidney Center of Hidaka Hospital in Takasaki, Japan.
Exclusion criteria were inability to give informed consent,
septicemia, and hospitalization for severe illness. We also
excluded patients\30 years and[90 years, patients whose
lipid data were unavailable, and patients who had a past
history of CVD based on their medical records, including
myocardial infarction (MI), congestive heart failure (CHF),
peripheral arterial disease (PAD), and/or stroke. The 259
remaining chronic HD patients (HD duration [6 months)
gave their consent to participate in this study. No patient
had an acute infection or malignancy at entry into the
study. We measured their baseline parameters in January
2006 and followed them up until September 2011. This
study was approved by the ethics review committee of the
hospital, and it was conducted in compliance with the
Declaration of Helsinki.
All patients had been on regular HD, 4–5 h each time,
three times a week at a blood flow rate of 180–200 ml/min
via their arteriovenous fistulas. A bicarbonate dialysate was
used at a flow rate of 500 ml/min in every patient. All HD
sessions were performed using a high-flux polysulfone
membrane dialyzer (BS-U, Toray Medical, Tokyo, Japan
or APA, Asahi Medical, Tokyo, Japan). No bacteria or
pyrogens grew out of the dialysate prepared from water
obtained by reverse osmosis. An endotoxin removal filter
was used to maintain the endotoxin concentration
\0.020 EU/ml. A blood sample was drawn at the start and
end of the dialysis session after 2-day interval. Blood was
drawn just before the start of a dialysis session. Blood
samples were collected after the patients had fasted for at
least 9 h. Serum albumin, TC, HDL-C, LDL-C, TG, and
C-reactive protein (CRP) were measured by routine labo-
ratory methods. When the TG level was \400 mg/dl, the
LDL-C level was calculated by using the Friedewald
equation (LDL = TC - HDL - TG/5) [7]. The non-
HDL-C level was calculated by subtracting the HDL-C
from the TC level. Lipid value means were obtained from
three measurements during the 3 months after entry. DM
was diagnosed based on the World Health Organization
(WHO) criteria [8]. The clinical status of each patient was
evaluated by a routine clinical examination before the
regular HD session. Systolic blood pressure (BP) was
measured with a mercury sphygmomanometer after the
patient rested in the supine position for 10–15 min, and
mean values of 1 month measurements were used in the
analysis. Information on treatment with statins was col-
lected from the medical records.
Data are expressed as the mean ± standard deviation
(SD). Patient-years were calculated from data of the
baseline examination and the date of death due to CVD
during the follow-up period. Cox proportional hazards
models were used to estimate the hazards ratio (HR) for
CV mortality and the 95% confidence interval (CI), with
adjustment for age, DM, dialysis vintage, systolic BP, and
serum albumin levels. All variables with a p value\0.1 in
the univariate analysis were included in the multivariate
regression model. Survival was estimated on the basis of
the Kaplan–Meier curves and compared using the log-rank
test. A receiver-operating characteristic (ROC) analysis
was performed. ROC curves are graphic representations of
the relationship between sensitivity and specificity of a
diagnostic parameter and are drawn through potential
points that represent different decision levels. The area
under the ROC curve (AUC) is a measure of the perfor-
mance of the test, and the larger the AUC, the better the
test performance. All statistical calculations were per-
formed using JMP version 9.0.1 software (SAS Institute
Japan, Tokyo, Japan); p values \0.05 were considered
statistically significant.
Results
During the 5-year follow-up period, we ultimately analyzed
data of 259 patients. Table 1 shows baseline characteristics
of participants, who consisted of 165 men and 94 women
with a mean age of 61.3 ± 11.9 years. Mean duration of
HD therapy was 10.9 ± 8.5 years. The cause of their
ESRD was primary renal disease in 197 patients and DM in
62 patients. The residual urine output of all patients was
within 100 ml/day. Fourteen patients (5.4%) were treated
with statins during the follow-up period. The mean serum
albumin and CRP levels were 3.7 ± 0.3 g/dl and
0.4 ± 0.8 mg/dl, respectively.
During the follow-up period, 44 patients (17.0%) died,
and 33 (12.7%) of the deaths were due to CVD. The CVD
was CHF in 19 patients, acute MI in six, PAD in three,
stroke in two, cardiac sudden death in two, and pulmonary
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hypertension in one. The non-CVD causes of death consisted
of sepsis in five patients, pneumonia in two, peritonitis in
one, gastrointestinal perforation in one, malignancy in one,
and gastrointestinal bleeding in one. Table 2 shows the
results of univariate Cox proportional hazards analysis for
predictors of CV mortality. Univariate analysis revealed that
the following characteristics were significantly associated
with higher CV mortality rates: older age, presence of DM,
shorter dialysis vintage, higher systolic BP, lower serum
albumin levels, and higher non-HDL levels. As shown in
Table 3, a multivariate analysis with adjustments for age,
DM, dialysis vintage, systolic BP, and serum albumin and
lipid levels showed that non-HDL-C was an independent
predictor of CV mortality (HR 1.015, 95% CI 1.004–1.025,
p = 0.0083) and the HR of non-HDL-C was similar to those
of TG (HR 1.008, 95% CI 1.002–1.013, p = 0.0078).
To identify the lipid parameters of HD patients that were
the best marker of CV mortality, an ROC analysis was
performed. The plots of non-HDL-C in Fig. 1 show the
similar specificity and sensitivity for evaluating CVD
mortality in HD patients (AUC 0.62416; p = 0.0366;
cutoff value 111.0 mg/dl). Even though the AUC values of
TC and LDL-C were similar to those of non-HDL-C, there
was no statistically significant difference according to each
cutoff point.
Patients were divided into tertiles according to their
serum non-HDL-C levels, as follows: T1 B90 mg/dl; T2
91–115 mg/dl; T3 C116 mg/dl. As shown in Fig. 2, the
Kaplan–Meier survival curves of HD patients showed
significant differences in CV mortality between tertiles
with respect to serum non-HDL-C levels (p = 0.0165).
Survival rate in the highest tertile (non-HDL-C C116 mg/
dl) was significantly higher than in the other two tertiles
(non-HDL-C B115 mg/dl).
Discussion
The results of this study showed that serum non-HDL-C
level was an independent predictor of CV mortality in
Table 1 Baseline characteristic of the study population
Patient characteristics
Number 259
Age (years) 61.3 ± 11.9 (31–90)
Men 165 (63.7%)
Smoker 28 (10.8%)
Dialysis vintage (years) 10.9 ± 8.5 (0.6–33.7)
Diabetes mellitus 62 (23.9%)
Body mass index (kg/m2) 21.4 ± 3.9 (6.7–44.7)
Systolic BP (mmHg) 138.7 ± 22.7 (75–208)
Hemoglobin (g/dl) 10.2 ± 1.0 (7.5–13.5)
Albumin (g/dl) 3.7 ± 0.3 (2.7–4.5)
C-reactive protein (mg/dl) 0.4 ± 0.8 (0–7)
Phosphorus (mg/dl) 6.0 ± 0.8 (5.2–6.8)
TC (mg/dl) 151.0 ± 33.1 (63–246)
LDL-C (mg/dl) 84.8 ± 27.5 (19–187)
HDL-C (mg/dl) 44.0 ± 13.3 (18–92)
Non-HDL-C (mg/dl) 107.0 ± 32.0 (36–207)
Triglyceride (mg/dl) 110.9 ± 63.5 (33–457)
Statins 14 (5.4%)
CVD cardiovascular disease, BP blood pressure, TC total cholesterol,
LDL-C low-density lipoprotein cholesterol, HDL-C high-density
lipoprotein cholesterol, Non-HDL-C non-high-density lipoprotein
cholesterol = TC - HDL-C
Table 2 Univariate Cox proportional hazards analysis showing
predictors of cardiovascular mortality in the study population
HR 95% CI p value
Age 1.056 1.024–0.089 0.0004
Gender (male) 1.173 0.581–2.511 0.6635
Diabetes 3.121 1.551–6.194 0.0018
Dialysis vintage 0.938 0.888–0.984 0.0067
Body mass index 1.011 0.919–1.091 0.8114
Systolic blood pressure 1.017 1.001–1.032 0.0354
Hemoglobin 0.909 0.634–1.296 0.6017
Albumin 0.288 0.106–0.817 0.0197
Phosphorus 0.889 0.665–1.181 0.4207
C-reactive protein 1.276 0.884–1.614 0.1625
TC 1.009 0.999–1.019 0.0738
HDL-C 0.989 0.962–1.017 0.4375
LDL-C 1.010 0.999–1.022 0.0739
Non-HDL-C 1.011 1.001–1.021 0.0280
Triglyceride 1.004 0.999–1.009 0.0803
HR hazards ratio, CI confidence interval, TC total cholesterol, HDL-C
high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol, Non-HDL-C
non-high-densitylipoprotein cholesterol = TC - HDL-C
Table 3 Multivariate Cox proportional hazards analysis showing
predictors of cardiovascular mortality in the study population
HR 95% CI p value
Age 1.064 1.026–1.105 0.0008
Diabetes 3.660 1.507–8.927 0.0044
Dialysis vintage 0.984 0.928–1.038 0.5690
Systolic blood pressure 0.999 0.983–1.016 0.9487
Albumin 0.444 0.124–1.604 0.2147
TC 1.013 1.003–1.023 0.0106
LDL-C 1.013 1.000–1.025 0.0514
Non-HDL-C 1.015 1.004–1.025 0.0083
Triglyceride 1.008 1.002–1.013 0.0078
HR hazards ratio, CI confidence interval, Non-HDL-C non-high-
density lipoprotein cholesterol = TC - HDL-C
Clin Exp Nephrol (2012) 16:767–772 769
123
chronic HD patients and that non-HDL-C was a significant
marker of CV mortality in a cohort of HD patients. These
results were consistent with the epidemiology in the gen-
eral population.
Liu et al. [9] reported that serum non-HDL-C level is a
stronger predictor of coronary heart disease risk than the
serum LDL-C level based on data sets from the Framing-
ham Heart Study (2,693 men; 3,101 women). In the Suita
study, a total of 4,694 men and women aged 30–74 years
with no history of CVD or use of lipid-lowering medica-
tion, a fasting blood sample was collected, and they were
followed up for 11.9 years [10]. During the follow-up
period, there were 80 incident MIs and 139 strokes. The
HR for MI was higher (2.97; 95% CI 1.26–6.97) for the top
quintile according to serum non-HDL-C levels (C180 mg/
dl in men and C189 mg/dl in women) compared with the
lowest quintile (\123 mg/dl in men and \143 mg/dl in
women). Analysis of trends showed a significant positive
relationship between MI incidence and serum non-HDL-C
levels (p = 0.02). More recently, Kitamura et al. [11]
analyzed data from 8,132 adults aged 40–69 years with no
history of stroke or coronary heart disease and found that
higher serum non-HDL-C levels were associated with an
increased risk of coronary heart disease. Thus, serum non-
HDL-C levels have been found to be an independent pre-
dictor of CVD in the general population.
Nishizawa et al. [12] reported for the first time that non-
HDL-C is an independent predictor of CV mortality based
on the Kaplan–Meier curves of a cohort of HD patients, but
because the authors were unable to obtain sufficient
information on CV mortality at baseline, pre-existing CVD
may have confounded the results of an association between
serum non-HDL-C and CV deaths during the follow-up
period. In this study, we performed ROC analysis accord-
ing to each cutoff value of serum lipids in order to evaluate
the sensitivity and specificity of a diagnostic parameter.
Moreover, Shoji et al. [13] performed an observational
study of 45,390 HD patients with no history of MI or stroke
at the end of 2003, extracted from a nationwide dialysis
registry in Japan, in which a multivariate logistic regression
analysis showed that incident MI was positively associated
with non-HDL-C and inversely with HDL-C during a
1-year follow-up period. Among patients who experienced
a new MI or stroke, the risk of death was not associated
with their serum HDL-C or non-HDL-C levels but with
older age, lower BMI, and higher CRP levels, suggesting
that dyslipidemia was associated with increased risk of
incident atherosclerotic CVD and that protein energy
wasting and inflammation were associated with increased
risk of death after CVD events.
The serum non-HDL-C level is the sum of the LDL-C,
intermediate-density lipoprotein-C, and very-LDL-C lev-
els, and serum non-HDL-C levels are strongly correlated
with ApoB levels. It has therefore been suggested that non-
HDL-C levels may be a better marker of atherogenic
cholesterol than LDL-C levels [4]. The non-HDL-C level
can be calculated easily by subtracting the HDL-C level
from the TC level. As TC and HDL-C data are similar
whether measured in the fasting or nonfasting state, non-
HDL-C is a reliable measure for HD patients [14, 15].
Because LDL-C data are calculated using the Friedewald
equation, elevated TG levels, even in the fasting state,
result in LDL-C levels that may not reflect the atherogenic
burden. Wanner and Krane [16] suggested that the non-
HDL-C level should be used as the primary target of
treatment in HD patients and that the non-HDL-C level is
an integrated index for atherogenic lipoproteins and is
unaffected by eating.
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Although epidemiological studies have shown that treat-
ment of HD patients with statins is accompanied by lower
CV mortality [17–19], prospective, randomized trials of the
potential beneficial effect of statins in this patient population
have yielded disappointing results. In this study, statins were
prescribed to CKD patients when their serum LDL-C levels
were[130 mg/dl. The Die Deutsche Diabetes Dialyse (4D)
trial enrolled 1,255 diabetic HD patients and randomized
them to receive either placebo or 20 mg/day of atorvastatin
[20], but after a mean follow-up period of 2.4 years, ator-
vastatin had not significantly reduced the risk of the com-
posite primary end point (CV death, nonfatal MI, and stroke),
despite a significant 42% reduction in LDL-C concentration
[21]. Several mechanisms have been proposed to explain the
failure of statins to improve CV outcomes of HD patients. It
has been suggested that the initiation and progression of
atherosclerotic disease in this population may have a dif-
ferent pathophysiological basis, including arterial wall cal-
cification and inflammation, whereas other investigators
emphasize that lipoproteins other than LDL-C may play a
significant role in the initiation and progression of coronary
atherosclerosis [22, 23]. Further study is needed to elucidate
the effect of statin therapy targeted at serum non-HDL-C
levels in HD patients on their CV mortality.
There were several limitations to this study. First, sample
size and number of events were small, and despite careful
adjustments in our statistical analyses, it was impossible to
rule out the presence of residual confounding factors. We
used Cox regression models adjusted by serum albumin level
as a covariate for malnutrition and inflammation, as previ-
ously reported [24]. Second, it is likely that the prevalence of
CV events was lower, as study participants were relatively
younger and included fewer diabetic patients. In addition,
serum lipid levels of the study population were relatively
low, including cases with an extremely low range. Third,
CHF was a major cause of CV mortality, and it may not
represent atherogenic CVD in HD patients. The inclusion of
CHF as a cause of CV death may have diluted the role of
atherogenic CVD in CV mortality. However, most CHF was
based on ischemic heart disease accompanied by ST-T
changes on the electrocardiogram (data not shown). Taking
these limitations into consideration, the results of this study
do not conflict with the relationship between serum non-
HDL-C levels and CV mortality.
Conclusion
The results of this study show that serum non-HDL-C level
is a significant predictor of 5-year CV mortality in chronic
HD patients. A better understanding of the biological role
of non-HDL-C is needed to corroborate its suitability as a
target of lipid-lowering therapy in HD patients.
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